Concise review: Getting to the core of inherited bone marrow failures by Adam S et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Adam S, Melguzo Sanchis D, El-Kamah D, Samarasinghe S, Alharti S, 
Armstrong L, Lako M.  
Concise review: Getting to the core of inherited bone marrow failures.  
Stem Cells (2016) 
DOI: http://dx.doi.org/10.1002/stem.2543  
 
Copyright: 
© 2016 The Authors. Stem Cells published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. 
This is an open access article under the terms of the Creative Commons Attribution License, which 
permits use, distribution and reproduction in any medium, provided the original work is properly cited. 
 
Date deposited:   
19/12/2016 
Concise Review: Getting to the Core of Inherited
Bone Marrow Failures
SOHEIR ADAM,a,b DARIO MELGUIZO SANCHIS,c GHADA EL-KAMAH,d SUJITH SAMARASINGHE,e
SAMEER ALHARTHI,f LYLE ARMSTRONG,c MAJLINDA LAKOc
Key Words. Inherited bone marrow failures • Human embryonic stem cells • Human induced
pluripotent stem cells • Animal models
ABSTRACT
Bone marrow failure syndromes (BMFS) are a group of disorders with complex pathophysiology
characterized by a common phenotype of peripheral cytopenia and/or hypoplastic bone mar-
row. Understanding genetic factors contributing to the pathophysiology of BMFS has enabled
the identification of causative genes and development of diagnostic tests. To date more than 40
mutations in genes involved in maintenance of genomic stability, DNA repair, ribosome and
telomere biology have been identified. In addition, pathophysiological studies have provided
insights into several biological pathways leading to the characterization of genotype/phenotype
correlations as well as the development of diagnostic approaches and management strategies.
Recent developments in bone marrow transplant techniques and the choice of conditioning reg-
imens have helped improve transplant outcomes. However, current morbidity and mortality
remain unacceptable underlining the need for further research in this area. Studies in mice
have largely been unable to mimic disease phenotype in humans due to difficulties in fully rep-
licating the human mutations and the differences between mouse and human cells with regard
to telomere length regulation, processing of reactive oxygen species and lifespan. Recent advan-
ces in induced pluripotency have provided novel insights into disease pathogenesis and have
generated excellent platforms for identifying signaling pathways and functional mapping of
haplo-insufficient genes involved in large-scale chromosomal deletions–associated disorders. In
this review, we have summarized the current state of knowledge in the field of BMFS with spe-
cific focus on modeling the inherited forms and how to best utilize these models for the devel-
opment of targeted therapies. STEM CELLS 2016; 00:000–000
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Bone marrow failure syndromes are characterized by a common phenotype of peripheral cyto-
penia and/or hypoplastic bone marrow. Great strides have been made in the last 20 years both
scientifically and clinically resulting in identification of more than 40 causative genes and
improved transplant outcomes. In this review, we summarize the most recent findings achieved
through application of animal models and stem cells which have generated important insight
for disease physiopathology and improved patient care.
INTRODUCTION
Bone marrow failure syndromes (BMFS) are
rare diseases characterized by peripheral cyto-
penias and/or hypoplastic bone marrow and
can either be inherited or acquired [1–3]. The
purpose of this review is to discuss the meth-
ods by which we may create in vitro models of
these conditions, therefore we will focus upon
inherited BMFS since although it is possible to
induce bone marrow failure in experimental
animals by administration of specific chemicals
[1], the development of methods to replicate
the phenotypes of acquired syndromes using
cellular models is currently difficult. In essence,
two broad mechanisms may be used to gener-
ate useful models of these diseases. Animal
models can work well in cases where the
genetic causes of the disease are known at the
level of DNA sequence since it is feasible to
engineer experimental animals in which the rel-
evant mutations play analogous role to their
human homolog. A significant problem with
this approach is that the physiology of experi-
mental animal species is often a poor match to
that of humans and genes known to carry dis-
ease causing mutations in humans may not
always have exactly the same mechanistic role
in animals such as mice or rats. An increasingly
attractive alternative is the use of pluripotent
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stem cell technology to create in vitro models of disease. Typi-
cally, this will involve “reprogramming” patient somatic cells
followed by differentiation to the types of cells most affected
by the disease. The behavior of these cells in vitro may repli-
cate many features of the disease making them a valuable
tool for increasing our understanding and identifying potential
treatments. We will discuss both of these modeling options in
turn.
BMFS have a broad clinical spectrum, sharing the failure
of hematopoietic stem cells (HSCs) to produce functional
blood cells and can affect patients of all ages [1–3]. More
than 30 inherited BMFS have been described and although
they are generally rare, conditions such as Fanconi anemia
(FA), dyskeratosis congenita (DKC), Diamond-Blackfan anemia
(DBA), Shwachman-Diamond syndrome (SDS), congenital ame-
gakaryocytic thrombocytopenia (CAMT), severe congenital
neutropenia (SCN) and thrombocytopenia absent radii (TAR)
are among the most common types. To date, more than 40
mutations in genes involved in maintenance of genomic sta-
bility, DNA repair and telomere biology have been identified
in inherited BMFS. In addition, pathophysiological studies
have provided insights into several biological pathways unrav-
eling genotype/phenotype correlations, diagnostic approaches,
and management strategies [1]. Given the association
between BMFS and genes involved in DNA repair mecha-
nisms, it is perhaps unsurprising that many of the BMFS have
a high predisposition toward malignancy [4, 5]. FA, DKC, SDS,
and CAMT often present with aplastic anemia and may evolve
into myelodysplastic syndrome (MDS) and acute myeloid leu-
kemia (AML). DBA, SCN, and TAR present with single cytope-
nia that rarely become aplastic but have increased risks of
leukemia. Solid tumors like head and neck and anogenital
squamous cell carcinoma are associated with FA and DC and
osteogenic sarcoma with DBA [4, 5]. A summary of the clinical
features of these diseases together with associated mutations
and therapeutic options is given in Table 1 [6–23].
Although rare, the clinical impact of BMFS is undoubtedly
significant. Experimental approaches to increase our under-
standing of these disorders are thus essential. Moreover, since
many of the causative genes play important roles in the
development and maintenance of the hematopoietic system,
studying their dysfunctions may provide further insights into
the production mechanisms of blood and immune cells. Thus,
investigations using animal and cellular models of the group
of diseases reviewed herein are of great value.
ANIMAL MODELS OF THE BONE MARROW FAILURE SYNDROMES
RECAPITULATE ONLY SOME DISEASE FEATURES
Several strategies may be applied to the generation of animal
models of BMFS with murine models being most typically
applied. Genetically modified mice can be generated by either
direct pronuclear injection of exogenous DNA into fertilized
zygotes or injection of genetically-modified murine embryonic
stem cells (ESC) into a blastocyst. Direct pronuclear injection
is technically demanding and often results in multiple, random
integrations of the injected DNA into the genome, and the
resulting disease phenotypes can vary depending on the
expression level of the injected transgene. Mouse ESCs have
the advantage that they can be genetically modified by means
of homologous recombination, a process by which a fragment
of genomic DNA introduced into a mammalian cell can recom-
bine with the endogenous homologous sequence. This process
is known as “gene targeting.” When such genetically modified
ES cells are introduced into a preimplantation embryo, they
can contribute to all cell lineages of the resulting chimeric
animal. If this contribution also comprises germ cells and the
chimeras are capable of breeding, it is possible to establish
lines of animals that are both heterozygous and homozygous
for the genetic alteration introduced into the ESCs. This pro-
cess can be used to add DNA sequences to specific genomic
loci (knock-ins), a protocol most often used to generate cell
lines with gene-specific reporter systems [24], or to create
point mutations with pinpoint accuracy. The technology for
generating mouse models using gene targeting is well devel-
oped and while discussion of this technology is outside the
scope of this article, excellent reviews on the subject are
available [25–27].
Gene editing of murine ESCs has been used to create a
number of genetically modified animals carrying mutations
associated with some of the more common forms of BMFS.
Despite the effectiveness of gene editing, these models do
not always demonstrate all the mechanistic or symptomatic
problems shown by humans. However, they have generated
useful data on the mechanisms of BMFS. An overview of ani-
mal models created to date is provided in Table 2 [28–59].
We hereby discuss individual examples of this approach:
Fanconi Anemia
The hallmark of FA is hypersensitivity to DNA cross-linking
agents, intolerance to oxidative stress and frequent chromo-
somal aberrations pointing to a DNA damage response defect,
all of which are used as diagnostic tests. To date 17 comple-
mentation groups have been identified and the genes encod-
ing these groups A (FANCA), B (FANCB), C (FANCC), D1
(FANCD1/BRCA2), D2 (FANCD2), E (FANCE), F(FANCF), G
(FANCG), I (FANCI/KIAA1794), J (FANCJ/BRIP1), L (FANCL), M
(FANCM), N (FANCN/PALB2), P (FANCP/SLX4/BTBD12), O
(FANCO/RAD51C), S (FANCS/BRCA1), and T (FANCT/UBE2T)
have been cloned [6–12, 60]. The FA core complex (FANCA, B,
C, E, F, G, L, and M), functions as an E3 monoubiquitin ligase
that responds to DNA damage or replication stress. The FA
core complex ubiquitinates FANCD2 and FANCI (the ID com-
plex) which then recruits FAN1 nuclease to help process and
cleave the DNA damage, followed by further recruitment of
FANCD1/BRCA2, FANCJ and FANCN to sites of DNA damage.
Once the mono-ubiquitinated FANCD2 and its associated part-
ners (FANCI, FANCD1, FANCJ, and FANCN) are correctly local-
ized on sites of DNA double strand breaks, they associate
with other DNA repair and checkpoint proteins such as NBS1,
ATR, CHK1 and CHK2, g-H2AX, RAD51, and BRCA1 to initiate
DNA repair and arrest the cell cycle [4, 5]. FANC proteins also
unwind DNA triplexes, remodel DNA structures such as Holli-
day junctions, D-loops and replication forks and channel the
DNA lesions toward error free DNA repair achieved by homol-
ogous recombination.
Targeted single deletions in mouse of various genes such
as Fanca, Fancc, Fancd2, and Fancg exhibit decreased long
term HSC repopulating activity and germ cell loss in addition
to cellular sensitivity to DNA interstrand crosslinks and oxida-
tive stress, but lack the clinical characteristic of FA including
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Table 2. Summary of key murine models of inherited bone marrow failure syndrome
Disease phenotype/
Gene name Affected systems References
FA/Fanca Homozygotes displayed FA-like phenotypes including growth retardation, microphthalmia, cranio-
facial malformations and hypogonadism. Homozygous females demonstrate premature repro-
ductive senescence and an increased incidence of ovarian cysts. Homozygous males exhibit an
elevated frequency of mis-paired meiotic chromosomes and increased apoptosis in germ cells,
implicating a role for Fanca in meiotic recombination. Fancc-/- Fanca-/- display the same phe-
notype as the single mutants suggesting that these two genes are epistatic.
[28, 29]
FA/Fancc Homozygotes do not show developmental abnormalities or hematological defects till 9-12
months of age. Male and female mutant mice have reduced numbers of germ cells and
females have markedly impaired fertility. The CFC capacity of hematopoietic progenitors is
abnormal and the cells are hypersensitive to gamma-interferon. Fancc-/-Tert-/- double mutant
mice have exacerbate telomere attrition when murine bone marrow cells experience high cell
turnover after serial transplantation and increase in the incidence of telomere sister chroma-
tid exchange. Fancc-/-Fancg-/- double-mutant mice develop spontaneous hematologic sequelae,
including bone marrow failure, acute myeloid leukemia, myelodysplasia and complex random
chromosomal abnormalities.
[30, 31]
FA/Fancd1 Homozygous null mutants are embryonic lethal with abnormalities including growth retardation,
neural tube defects, and mesoderm abnormalities; conditional mutations cause genetic insta-
bility and enhanced tumor formation; mutants with truncated BRCA2 protein survive, are
small, infertile, show improper tissue differentiation and develop lymphomas and carcinomas
[32]
FA/Fancd2 Homozygous mutant mice exhibit meiotic defects and germ cell loss. In addition, mutant mice
display perinatal lethality, susceptibility to epithelial cancer and microphthalmia. Homozygous
mice have smaller hematopoietic stem cell pool and reduced lymphoid progenitor frequency.
Fancd2-/-Aldh2-/- double homozygous mice are unusually sensitive to ethanol exposure in
utero, and ethanol consumption by postnatal double-deficient mice rapidly precipitates bone
marrow failure and spontaneously developed acute leukemia. Aged Aldh2-/-Fancd2-/- mutant
mice which do not develop leukemia, spontaneously develop aplastic anemia, with concomi-
tant accumulation of damaged DNA within the hematopoietic stem and progenitor cell pool.
[33-35]
FA/Fancg Females and males homozygous for targeted null mutations exhibit hypogonadism and reduced
fertility. Cytogenetic analysis shows somatic chromosome aberrations occurrence at a higher
spontaneous rate. Cells are also more sensitive to mitomycin C.
[36]
FA/Fanci These mice show craniofacial, vision, and eye abnormalities. [37]
FA/Fancn Homozygotes display embryonic lethality with impaired inner cell mass proliferation, impaired
gastrulation, absence of the amnion, somites and tail bud, and general improper
organogenesis.
[38]
FA/Fancm Homozygotes exhibit reduced female transmission, hypogonadism, premature death and
increased incidence of tumors.
[39]
FA/Fancp Homozygotes display exhibit preweaning lethality, reduced fertility, abnormal eye morphology,
abnormal skeletal morphology, hydrocephalus, chromosomal instability, early cellular replica-
tive senescence and abnormal lymphopoeisis. Mutant mice are characterized by blood cytope-
nia, premature senescence, accumulation of damaged chromosomes and hypersensitivity to
DNA cross linking agents.
[40]
FA/Fanco Mice homozygous for a null mutation display embryonic lethality. Mice carrying a null and a
hypomorphic allele have partial penetrance of male and female infertility due to defects in
meiosis.
[41]
FA/Fancs Homozygous null mutants are embryonic lethal with abnormalities including growth retardation,
neural tube defects, and mesoderm abnormalities; conditional mutations cause genetic insta-
bility and enhanced tumor formation; mutants with truncated BRCA1 protein survive, have a
kinky tail, pigmentation anomalies, male infertility and increased tumor incidence.
[42]
DKC/Dkc1 Early generation male mice hemizygous for a hypomorphic allele exhibit bone marrow failure,
dyskeratosis, extramedullary hematopoieis, splenomegaly, lung and kidney abnormalities,
increased tumor incidence, altered ribosome function. Decreased telomere length is noted
only in later generations.
[43]
DKC/Tert In spite of impaired telomerase function, homozygous mutant mice are overtly normal in early
generations. Impaired fertility has been reported in later generations for homozygotes of at
least one knockout allele. Homozygous Tert mice display short dysfunctional telomeres and
sustained increased DNA damage signaling and classical degenerative phenotypes upon suc-
cessive generational mattings and advancing age.
[44]
DKC/Tr Early generation mice homozygous for a null allele have intact telomeres and appear grossly
unaffected and healthy, whereas late generation mutants exhibit premature death, shortened
and dysfunctional telomeres, apoptotic and proliferative defects, infertility, and multi-organ
degenerative decline. Late-generation animals exhibit defective spermatogenesis, with
increased programmed cell death (apoptosis) and decreased proliferation in the testis. Prolif-
erative capacity of hematopoietic cells in the bone marrow and spleen is also compromised.
These progressively adverse effects coincide with substantial erosion of telomeres and fusion
and loss of chromosomes.
[45]
DKC/Tinf2 Targeted disruption of this gene results in embryonic lethality prior to E7.5 through a mecha-
nism that is independent of telomerase function. Second and third generation heterozygotes
develop mild pancytopenia, consistent with hematopoietic dysfunction in DKC, as well as
diminished fecundity.
[46]
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marrow aplasia, hematological abnormalities, and early life
tumorigenesis [28–33]. Cells cultured from all FA mouse mod-
els show accumulation of chromosomal aberrations when
exposed to DNA cross-linking agents, suggesting some degree
of functional conservation of the FA DNA repair pathway
between species. Cells present in the spleens of the mutant
mice are highly susceptible to accumulation of unrepaired
chromosomal aberrations following exposure to DNA cross-
linking agents and abnormal sensitivity to IFNg. Moreover,
Fancc-/- mice are particularly sensitive to the action of the
DNA cross-linking agent, Mitomycin C, administration of which
causes bone marrow failure within 3-8 weeks. A key inference
from these data is that loss of function mutations of single
genes of the FA pathway in mice do not compromise short-
term survival but rather restrict the capacity of mice to repair
damage induced by environmental insults or DNA damaging
agents. This implies that loss of additional genes might be
needed to recapitulate the characteristics of human FA. Thus,
several double mutant mouse models have been created to
analyze processes that may enhance the development of FA.
This approach is exemplified by the observation that while
Fancc-/- mice do not develop bone marrow hypocellularity,
the Fancc-/- and Sod1-/- double mutants develop this feature
and go on to develop anemia and leucopenia, providing some
evidence that oxidative stress contributes to bone marrow
failure in FA [61]. More recently, double mutants of Fancd2-/-
and Aldh2-/- have been generated and these exhibit unusual
sensitivity to endogenous aldehydes in utero [34, 35]. Ethanol
(a source of exogenous of acetyldehyde) exposure by postna-
tal double-deficient mice rapidly precipitates BMFS and results
in spontaneous development of acute leukemia, suggesting
that the FA pathway counteracts acetaldehyde induced toxici-
ty. Other promising models include the Btbd12 knockout
mouse, the ortholog of Slx4 (Fancp) which mimics many fea-
tures of FA including peripheral cytopenia, reduced fertility,
dysmorphic features, ocular abnormalities, hydrocephalus,
chromosomal instability, accumulation of damaged chromo-
somes, hypersensitivity to DNA crosslinking agents and abnor-
mal lymphopoeisis [40]. Whilst the data generated from such
models are interesting, the need to create double knockouts
to recapitulate, even in part the phenotype which in humans
results solely from mutations in the FANC genes remains a
significant problem. The potential greater susceptibility of
mice to sustain and retain DNA damage and/or the presence
Table 2. Continued
Disease phenotype/
Gene name Affected systems References
DKC/Rtel1 Homozygous null mice display embryonic lethality with abnormal development of the neural
tube, brain, heart, vasculature, placenta, and allantois and chromosomal abnormalities in dif-
ferentiating cells.
[47]
DKC/Ctc1 Mice homozygous for a targeted allele exhibit defective telomere replication that leads to stem
cell exhaustion, bone marrow failure and premature death.
[48]
DBA/Rps6 Conditional Rps6 mice using CD4-Cre abolishes T cell development. [49]
DBA/Rps7 Rps7 disruption results in decreased body size, abnormal skeletal morphology, mid-ventral white
spotting, and eye malformations. Rps7 mutants display overt malformations of the developing
central nervous system and deficits in working memory; however they do not show anemia
or hyperpigmentation.
[50]
DBA/Rps19 Homozygous null embryos die prior to the formation of a blastocyst. Mice heterozygous for
some point mutations show pigment defects affecting the feet and tail. However the hetero-
zygotes show a normal development of the hematopoietic system. Heterozygous missense
mutations of Rps19 show a mild macrocytic anemia reflecting the fact that mutations causes
a hypomorphic allele rather than true happloinsufficiency.
[51]
DBA/Rps20 Heterozygous missense mutations of Rps20 show a mild macrocytic anemia reflecting the fact
that mutations causes a hypomorphic allele rather than true happloinsufficiency.
[52]
SDS/Sbds Loss of Sbds gene results in early embryonic lethality, with homozygotes showing histological
abnormalities of the liver and accumulation of free cytoplasmic 40 S and 60 S subunits. Heter-
ozygotes have a normal phenotype.
[53]
CAMT/Mpl Mice homozygous for targeted mutations at this locus are unable to produce normal numbers
of megakaryocytes and platelets and display HSC deficiencies that are not limited to megakar-
yocytic lineages. These mice also have increased concentrations of circulating TPO.
[54]
SCN/Ela2 Homozygotes for a null allele show impaired neutrophil physiology, susceptibility to Gram (-)
bacterial infection, reduced sensitivity to xenobiotics and abnormal local Schwartzman
responses. Homozygotes for a knock-in allele show susceptibility to fungal infection and resis-
tance to endotoxic shock. Heterozygous mice do not show neutropenia.
[55]
SCN/HAX1 Mice homozygous for deletion of this gene fail to survive beyond 14 weeks of age. Apoptosis of
neurons in the striatum and cerebellum occurs as does loss of lymphocytes and neutrophils.
[56]
SCN/Gfi1 Homozygotes are severely neutropenic and accumulate immature monocytes in blood and bone
marrow. Their myeloid precursors cannot differentiate into granulocytes upon stimulation with
G-CSF; however they can develop into macrophages. Conditional knockouts indicate defects in
Th2 cell expansions and enhanced IFNg production.
[57]
SCN/Wasp Homozygous mutant females and hemizygous mutant males exhibit reduced numbers of periph-
eral blood lymphocytes and platelets, but increased numbers of neutrophils.
[58]
RS/Hoxa11 Homozygotes for targeted null mutations exhibit homeotic transformations affecting thoracic
and sacral vertebrae, and forelimb defects. Mutants are sterile due to malformed vas deferens
and cryptorchism in males, and defective uteri in females.
[59]
Abbreviations: CFC, colony-forming cell; G-CSF, granulocyte colony stimulating factor; FA, Fanconi anemia; HSCs, hematopoietic stem cells; IFNg,
interferon g; TPO, thrombopoietin.
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of alternate regulatory mechanisms for FANC proteins in
humans, indicate that murine FA models may not be optimal
tools to understand the pathophysiology of FA and develop
novel treatments. Furthermore, the nature of mutations in
various types of FA is extremely heterogeneous, including
point mutations, small insertions/deletions, splicing mutations,
and large intragenic deletions, which makes it difficult to rep-
licate exactly all human mutations through targeted gene
knock-ins/outs in the mouse system.
Dyskeratosis Congenita
DKC is the first disorder to be etiologically linked to mutations
in the telomere pathway [62]. About 70% of DKC patients
have identifiable germ-line mutations affecting genes respon-
sible for regulation and maintenance of telomeres [2]. To
date, nine genes have been associated with DKC phenotype;
DKC1, TERT, TERC, TINF2, WRAP 53, NOP10, NHP2, CTC1, and
RTEL1 [63, 64]. Two categories of mutations are found in DKC:
mutations that decrease telomerase activity including those
affecting Dyskerin (DKC1), TERC and TERT, and mutations that
impair telomerase recruitment in genes such as TIN2 [3]. The
resultant telomere shortening leads to cell senescence and
stem cell exhaustion. Moreover, telomere attrition results in
chromosomal fusion and genetic instability, which is at the
root of development of secondary malignancies in affected
individuals [4].
Gene editing of murine ESC has been used to model loss
of function for most of these genes; however concerns about
differences in telomere maintenance between mouse and
human can limit the utility of these models. Although the
telomeric DNA sequence is identical in both species, abnor-
malities in telomere maintenance and in telomerase function
do not coincide in phenotype in humans and mice. Most
strains of laboratory bred mice have telomeres 5-10 times
longer than humans, whereas absence of telomerase activity
is only phenotypically present over several generations in
mice and even heterozygous mutations affecting the telome-
rase reverse transcriptase subunit (hTERT) cause defects in
stem cell proliferation, organ regeneration and incidence of
cancer in humans. Patients with telomerase dysfunction
including DKC, frequently develop aplastic anemia whereas
telomerase-null murine models display only modest hemato-
poietic defects.
Early models of DKC (hypomorphic DKC1) display a DKC-
like phenotype reflected in the increased evidence of tumors
in the mammary glands and lungs (not in gut and skin as in
human DKC patients), splenomegaly, dyskeratosis of the skin,
anemia, yet in the early generations there is no obvious telo-
merase dysfunction [43]. Similar findings have been reported
for Tert-/- and Tr-/- early generations where classical degenera-
tion phenotypes and telomere dysfunction could only be
achieved after successive mattings which result in substantial
erosion of telomeres and fusion and loss of chromosomes
[44, 45]. These observations are consistent with the probabili-
ty that mouse telomeres are too long to erode sufficiently in
a single mouse lifespan to generate all the DKC symptoms
observed in humans. Deletion of the RNA template subunit
(mTERC) in mice that already have short telomeres is a more
effective means of replicating the DKC phenotype. Similarly,
double knockout of Pot1b (an ortholog of the “protection of
telomeres protein” encoding gene) and Terc results in
enhanced telomere degradation (rather than progressive telo-
mere shortening) and results in premature death, BMFS, sig-
nificant anemia, leukopenia and thrombocytopenia. That such
double knockout is necessary to create a DKC-like phenotype
calls into question once more the validity of murine models
of human disease. Further, the question of how stem cell fail-
ure occurs at all in these models also arises. Loss or function-
al failure of HSC clearly occurs after significant erosion of
telomeric DNA but whether this is due to induction of senes-
cence by critically short telomeres is not yet clear. Other
mechanisms to account for the dysfunctional HSC of DKC
patients have been proposed such as defects in ribosome bio-
genesis leading to defects in the processing of 18s rRNA [65].
This process has been modeled in zebrafish by knockdown of
the gene Nop10 and this model does show enhanced HSC
apoptosis but to our knowledge; however this has not been
attempted in mice.
A further complication with disease modeling of DKC
using targeted gene knockdown in mice is the nature of
human mutations. In most documented cases to date, partial
loss of function as well as haploinsufficiency (for example
DKC1 in de novo DKC) and in some cases dominant negative
mutations (for example TINF2 in autosomal dominant DKC)
have been reported in addition to loss of function mutations.
Whilst, loss of function mutations can be modeled with tar-
geted gene approaches in mice, partial loss of function and
haploinsufficiency are difficult to mimic unless the human
mutation is introduced into the mouse germ line or ESC using
the most recent gene editing technique (for example Crispr/
Cas9 method). This however can be easily superseded by the
iPSC disease modeling approach which enables the assess-
ment of human mutations in a dish by reprogramming of
patient specific somatic cells.
The severity of the mutations is also an important aspect
which cannot always be matched between mouse models and
human patients. This is best exemplified by a rare and severe
form of DKC, Hoyeraal-Hreidarsson syndrome, which is caused
by mutations in a subset of genes, including DKC1, TINF2,
TPP1 and RTEL1 and manifests early in childhood. Human
patients with two mutations in the TPP1 gene (single amino
acid deletion1missense mutation) require regular platelet
and red blood cell transfusions for bone marrow failure [66];
however homozygous mouse mutants of Tpp1 were embryon-
ic lethal [67], suggesting that the “blunt” loss of function cre-
ated by targeted gene knock-out in mice enables creation of
much more severe phenotypes compares to human, but also
result in loss of viability preventing further disease modeling.
This also raises the intriguing question as to why the mouse
homozygous mutants are lethal if telomeres in mice are much
longer than humans, which suggests that the simple view of
telomere length in stem cell renewal is not as important as
telomere protection from degradation which is essential for
maintaining the ends of chromosomes and genomic stability
in proliferating stem and progenitor cells.
Diamond-Blackfan Anemia
Mutations in ribosomal protein genes that encode structural
components of the ribosome responsible for the correct
assembly of the ribosomal subunits are associated with the
abnormal pre-rRNA maturation patterns in DBA patients [68].
RPS19 gene mutations are found in 25% of DBA patients [69].
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Mutations resulting in haploinsufficiency or loss-of-function in
all genes identified so far include missense mutations, non-
sense mutations, splice mutations, insertions, deletions, and
rearrangements [5]. These mutations prevent the assembly of
ribosomal protein to form preribosomal particles, which in
turn activates nucleolar stress pathways that are at the center
of the pathophysiology of DBA. Some of the mutations in
RPS19 can affect the synthesis of the ribosomal protein by
altering transcription, splicing, or translation [70–72]. RPS19
function is essential for correct processing within ITS1 and
subsequent maturation of the 30 end of 18S rRNA. Inactiva-
tion of both copies of RPS19 genes in Saccharomyces cerevi-
siae yeast leads to complete arrest of small ribosomal subunit
synthesis [73]. Accumulation of large amounts of 21S pre-
rRNA was detected in DBA patients carrying RPS19 mutations.
This defect in pre-RNA maturation was also observed in
CD342 hematopoietic precursors, skin fibroblasts, and lym-
phoblastoid cell lines. As shown in Table 2, Rsp19-/- homozy-
gous mice are embryonic lethal, whilst heterozygous mice
either are normal or show a mild macrocytic anemia (depend-
ing on the nature of targeted gene event), indicating that
these models are unable to truly recapitulate the RPS19 hap-
loinsufficiency described in the human DBA patients. Mice
heterozygous for missense mutations of Rsp19 and for a simi-
lar ribosomal component Rsp20 show mild macrocytic anemia
indicating possible HSC dysfunction. Other models including
antisense oligonucleotide knockdown of Rpl11 in Zebrafish
show significant effects on early hematopoietic development
and defects in adult hematopoiesis such as reduced formation
and maturation of erythroid cells which is similar to the phe-
notype of DBA. Another informative model is the conditional
Rsp6 mouse where homozygous deletions of Rsp6 were
achieved through CD4-driven Cre recombinase resulting in
abrogation of T cell development. In contrast to homozygous
deletions, Rps6 haploinsufficiency although it did not impact T
cell maturation, it affected their proliferation. Together these
data suggest that blood cells with Rsp6 haploinsufficiency
may cope with ribosome synthesis under low cell prolifera-
tion; however this is severely compromised in tissues charac-
terized by rapid proliferation (such as the hematopoietic
system).
Shwachman-Bodian-Diamond
Knockouts of two genes implicated in Shwachman-Bodian-
Diamond syndrome (Sbds) and ribosomal protein 18 (Rps18)
which are central to ribosome function are unsurprisingly
embryonic lethal [74]. Approximately 90% of SDS patients
have mutations in the SBDS gene which shares 97% homology
with an adjacent pseudogene, SBDSP which contains deletions
and nucleotide changes preventing generation of a functional
protein. 75% of patients with SDS have SBDS mutations which
are acquired as result of gene conversion events from the
pseudogene SBDSP. Patients homozygous for SBDS mutations
have not been identified, suggesting that complete loss of
SBDS is likely to be lethal in humans. This is corroborated by
animal studies which have shown that loss of Sbds gene in
mice results in early embryonic lethality (Table 2), whilst het-
erozygous mice are completely normal, indicating once more
the inability of heterozygous mouse mutants to mimic the
precise nature of human SBDS mutations. While studies in
yeast have clearly shown disruption of ribosome biogenesis as
result of SBDS dysfunction, how this leads to a specific phe-
notype in the bone marrow of SDS patients remains to be
identified.
Severe Congenital Neutropenia
SCN is characterized by a defective neutrophil maturation
leading to severe infections. Human SCN-associated mutations
in ELA2, GFI1, and WASP appear not to be functionally null in
humans and this creates some difficulty when comparing the
phenotype of SCN in humans and animal models. A clear
example of this is provided by the Gfi1 knockout model which
shows a much more severe phenotype compared to patients
with SCN [75]. Similarly Ela2-/- mice display impaired neutro-
phil function, consistent with a role for elastase 2 in bacterial
killing; however heterozygous Ela2 mice do not show neutro-
penia. This suggests that to date there is no suitable animal
model for mimicking ELA2 causing SCN in man. For HAX1, all
three known human mutations lead to premature stop
codons during the translation stage and therefore it was
hoped that Hax1-/- knockout models would mimic the disease
phenotype. Unfortunately, Hax1-/- mice fail to survive past 14
weeks of age, thus preventing functional studies of this gene
in adulthood.
THE ADVANTAGES OF IN VITRO MODELING
From the range of studies described so far, it should be clear
that animal models of BMFS are at best only approximations
of the etiological mechanisms in humans. Thus, there is a
clear and largely unmet need to create alternative disease
models to further our mechanistic understanding of BMFS
and to explore management approaches. Despite huge efforts,
the last decades have witnessed an alarming failure to devel-
op new treatments. At the center of this dilemma is the fact
that animal disease models do not mirror human disease,
thus the drug is either ineffective or leads to unacceptable
toxicities in humans. Drug discovery based on affected human
models would yield superior results, but unfortunately affect-
ed tissues are often accessible only on deceased patients.
Such tissues are unsuitable for testing drug toxicity and effica-
cy as they reflect end stages of the disease. This is particularly
true for inherited BMFS since ex vivo expansion of HSC from
aplastic bone marrow is challenging [76].
The advent of human pluripotent stem cell technology
may offer a solution to these problems. Human embryonic
stem cells (hESCs) and more latterly, induced pluripotent stem
cells (iPSCs), are capable of indefinite in vitro expansion while
retaining the ability to differentiate into cell types characteris-
tics of most tissues found in the developing embryo. Reprog-
ramming somatic cells to pluripotency by ectopic expression
of four transcription factors expressed by ESC was first
reported in 2006 [77]. The products of such reprogramming
were termed “induced pluripotent stem cells” or iPSC by their
originator, Shinya Yamanaka. In the following year, human
iPSC (hiPSCs) were reported by Yamanaka’s and another group
[78, 79]. The pluripotency of iPSCs confers properties on these
cells particularly interesting for clinical research since iPSCs
can be patient-specific and disease-specific, thus providing a
promising platform for investigating the pathophysiology of a
specific disease and testing the effectiveness and toxicity of
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drugs in the cell of interest. Despite the need to overcome
some potential hurdles such as the acquisition of de novo
genetic alterations during reprograming, possible retention of
a small number epigenetic marks present in the somatic par-
ent cells and aberrant DNA methylation acquired during the
reprogramming process, which may affect the cell differentia-
tion capabilities, there is an increasing awareness of the value
of iPSC based disease modeling as a tool to further drug dis-
covery [80–83].
Differentiation of pluripotent stem cells toward patient
specific hematopoietic cell types is the basis of modeling
inherited BMFS. However, the major challenge is the genera-
tion of fully functional HSCs. Several studies have described
the generation of hematopoietic progenitors, but on further
differentiation in both in vitro and in vivo experimental mod-
els, such progenitors show a preference toward myeloid dif-
ferentiation so high long term engraftment efficiency and
multi-lineage differentiation of functional HSC in the bone
marrow of immune compromised mice remains challenging
[84–90]. Several patient specific hiPSCs lines from patients
with inherited BMFS have now been established. To maintain
clarity with respect to our discussion of animal models we
will describe hiPSCs based models of BMFS in the same order
before discussing additional in vitro modeling attempts.
Fanconi Anemia
The processes of reprogramming needed to generate hiPSCs
is dependent on enhanced cellular proliferation during the ini-
tial stages of reprogramming which requires the activation of
DNA repair pathways to ensure maintenance of genomic sta-
bility. Thus, it is quite difficult to derive hiPSCs from somatic
cells of patients suffering from DNA repair disorders, which
renders the development of a hiPSCs based model of FA diffi-
cult to achieve. Initial studies suggested that reprogramming
of FA patient specific hiPSCs was only possible after genetic
complementation of the donor fibroblasts prior to reprogram-
ming or when reprogramming was performed under hypoxic
conditions [91, 92]. The increased incidence of unrepaired
DNA double strand breaks in FA patients was thought to con-
tribute to this. An alternative approach to modeling FA is to
knockdown the expression of FA genes in otherwise healthy
hESCs and some data were generated by Tulpule et al. by
RNA interference mediated knockdown of FANCD2 and FANCA
[93]. Differentiation of hESCs subjected to this approach
yielded hematopoietic progenitors with reduced ability to
mature into functional CD451 cells. Furthermore, these FA-
deficient hematopoietic progenitors displayed an abnormal
transition of embryonic to adult globin expression, indicating
an impaired hematopoietic development with a bias toward
primitive populations. Yung and coworkers succeeded to
reprogram FA-C fibroblasts under normoxic conditions,
although the reprogramming efficiency was much lower com-
pared to fibroblasts taken from unaffected controls [94].
These hiPSCs showed frequent chromosomal abnormalities
and were unable to generate bona-fide teratomae with contri-
bution to cell types representative of all three embryonic
germ layers. Despite this, the FA-C hiPSCs were able to differ-
entiate into hematopoietic progenitors albeit ones with signif-
icantly reduced clonogenicity and enhanced levels of
apoptosis. A greater percentage of the phenotypic hematopoi-
etic progenitors from FA patient specific iPSC were in S-phase
of the cell cycle indicating a higher rate of proliferation and
the possibility that this is a compensatory response to the
higher levels of apoptosis. Replenishment of hematopoietic
progenitors at this higher rate contributes to the development
of more chromosomal abnormalities and replicative exhaus-
tion of the stem cell population. Whilst the increased apopto-
sis of hematopoietic progenitors and accumulation of genomic
instabilities were features already described in mouse models,
the role of FA pathway during somatic cell-induced reprog-
ramming and the availability of FA-specific cells for drug dis-
covery are novel aspects which could only be achieved
through the hiPSCs disease modeling approach. For regenera-
tive medicine, caution should be exercised to obtain patient
specific cells as early as possible and to ensure they are
genetically complemented with the functional alleles before
the reprogramming and differentiation process in order to
maintain genomic stability.
Dyskeratosis Congenital
hiPSCs have been derived from DKC patients with mutations
in DKC1, TERC, TERT, and TCAB1 which display normal karyo-
types and hallmarks of pluripotency as described earlier
[95–98]. Since telomerase activity is normally increased during
the reprogramming process, by upregulation of the catalytic
subunit hTERT, one might expect that DKC specific iPSC would
be less useful as disease models. This is probably true for DKC
cases involving mutations in the RNA template component
(TERC) since hTERT reactivation appears to be sufficient to
overcome the reduction in telomerase activity resulting from
the TERC mutations. However, attempted upregulation of an
hTERT gene carrying heterozygous mutations merely produces
a dysfunctional hTERT protein, which cannot function effec-
tively within the telomerase holoenzyme complex. For this
reason, hiPSCs lines derived from patients with such hTERT
mutations display shortened telomeres following extended
culture which ultimately prevents their self-renewal. This phe-
notype is more pronounced in hiPSCs lines derived from
patients with X-linked DKC where the mutation of DKC1 blocks
telomerase assembly and disrupts telomere elongation [95].
The severity of the telomerase dysfunction depends upon the
precise nature of the DKC1 mutation; hiPSCs lines carrying
Q31E and DL37 mutations maintained the same telomere
length as the parental fibroblasts; however the A353V mutant
DKC- hiPSCs presented shorter telomeres compared to the
parental fibroblasts suggesting that this A353V mutation has a
more severe effect on the telomere maintenance process.
Diamond-Blackfan Anemia
DBA-hiPSCs have been generated from patients with muta-
tions in RPS19 and RPL5 genes [99]. These DBA-hiPSCs lines
exhibited defective assembly of ribosomal subunits and pro-
duction of ribosomal RNA as well as impaired generation of
hematopoietic progenitors with erythroid lineages being the
most affected. These features recapitulate the phenotype
observed in DBA patients, thus providing an excellent tool to
investigate DBA. Genetic correction of the affected genes
restored the expression of deficient ribosomal proteins result-
ing in an increase of the ribosome biogenesis, normal genera-
tion of hematopoietic progenitors and erythroid cells. Using
patient specific lines and hematopoietic differentiation as a
model, the same authors described for the first time the
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dysregulation of noncanonical TGFb signaling pathway mediat-
ed by p-JNK which may be the underlying cause for abnormal
hematopoiesis in DBA-hiPSCs, for TGFb signaling is inhibitory
to hematopoietic commitment [100]. These studies clearly
indicate that patient specific hiPSCs can provide novel insights
into the disease pathogenesis as well as a platform for regu-
lating critical pathways involved in hematopoiesis and ery-
throid differentiation via the use of small molecules.
Shwachman-Bodian-Diamond
hiPSCs have been generated from patients with reduced SBDS
expression which display dysfunctional ribosome assembly
[101]. Upon differentiation to pancreatic cell lineages, the
SDS-hiPSCs and hESCs showed increased cell death and
impaired organization of the acinar-like structures, which led
to progressive loss of exocrine tissue. SDS-hiPSCs were able to
differentiate to mesodermal lineages; however a reduced per-
centage of hematopoietic cells and colony forming potential
was noted together with increased levels of proteases in cul-
ture supernatant. The residual SBDS expression in some
patient specific lines led to absence of the pancreatic pheno-
type and presence of hematopoietic defects only, similar to
previous clinical observations in SDS patients, thus further
corroborating the genotype-phenotype correlation. Despite
this observed variability, both the pancreatic and/or hemato-
poietic phenotype could be rescued either by the forced
expression of the SBDS transgene or by the use of protease
inhibitors in the culture media, thus providing a clear example
of drug-reversible phenotype using the hiPSC model for these
patients and providing novel therapeutic insights.
Severe Congenital Neutropenia
Several groups have reported the generation of patient spe-
cific hiPSCs carrying mutations in genes involved in SCN such
as ELA2 and HAX1 [102, 103]. Upon differentiation to neu-
trophils using a defined feeder free method, SCN-hiPSCs
lines show developmental arrest at the myeloid progenitor
stage resulting in decreased pool of myeloid progenitors,
impaired response to G-CSF stimuli as well as increased lev-
els of apoptosis in neutrophils, reminiscent of abnormal
granulopoiesis observed in SCN patients. This phenotype
could be rescued by retroviral transduction of HAX1 and
ELA2 in the respective isogenic hiPSCs lines. In a recent
study, Nayak et al. identified the mislocalization of the ELA2
gene encoding protein neutrophil elastase (NE) as the induc-
tor of the UPR/ER stress, dysfunctional differentiation and
apoptosis and demonstrated that the SCN phenotype could
be corrected by addition of the NE inhibitor called sivelestat
to the culture media of the hiPSC-derived myeloid progeni-
tors. Together these studies indicate that SCN-hiPSCs provide
an excellent platform for high-throughput screening of drugs
to reverse various congenital neutrophil disorders as well as
better understanding of disease pathogenesis which can be
clinically exploited to achieve therapeutic responses using
lower doses of G-CSF combined with targeting to correct NE
mislocalization.
Recent progress in the field of genome editing is giving
iPSC technology a solid framework for disease modeling and
for future clinical therapies. Previous gene therapies carried
out via transient or constitutive expression of transgenes
were undermined by the possibility of transgene integration
into loci that conferred uncontrolled cellular proliferation
resulting in tumorigenesis. To date the development of robust
and efficient human genome engineering tools including zinc-
finger nucleases (ZFNs), transcription activator-like effector
nuclease (TALEN) and Crispr-Cas9 systems which permit in situ
gene editing with reduced risk of off-site mutagenesis has
propelled forward the genome engineering approaches [104].
In particular, the Crispr/Cas9 system stands out from the oth-
er gene editing tools for its precision, versatility and simplici-
ty. Early applications of in situ gene editing approaches
involved introduction of specific gene mutations for disease
modeling studies in various species ranging from fruit flies to
Man [105–107]. Currently genome editing tools are being
used to correct genetic defect in iPSC harboring disease-
causing mutations providing insights on the pathophysiology
of hematological disorders (such as b-thalassemia or hemo-
philia) and confirming disease causality of the corrected
genetic defect [108–112].
To date, a handful of studies have reported the success-
ful use of genome editing tools for the study of BMFS. For
example, ZFN mediated disruption of the FANCA gene in
wildtype hESC to create a FA disease model and restoration
of specific mutations in the FANCC gene in wild type fibro-
blasts via the Crispr/Cas9 system have been reported [113,
114]. Recently, Bluteau et al. inactivated the REV7 using the
Crispr/Cas9 approach and showed that this resulted in
increased cellular hypersensitivity to DNA interstrand cross-
link drugs (ICL) as well as an impaired ability of the mouse
hematopoietic progenitor cells to form hematopoietic
colonies in Colony-Forming Unit (CFU) assay, resulting in
characterization of a new gene in the FA pathway [116].
Combination of genome editing tools with the iPSC technolo-
gy has the potential to result in generation of disease free
iPSC derived hematopoetic cells that can be used in poten-
tial cell based therapies. Rio et al. reported in 2014 the suc-
cessful phenotypic correction of FANCA defective fibroblasts
and later generation of disease-free iPSC which upon hema-
topoetic differentiation could generate similar number of
hematopoietic colonies compared to healthy cord blood pro-
genitor cells [117]. Likewise, the disease-free iPSC-derived
hematopoetic progenitors proved to be resistant to exposure
to drugs that cause interstrand cross-links in DNA thus dem-
onstrating the reversal of disease phenotype using novel and
safe gene editing tools.
Application of iPSC technology as a platform for gene cor-
rection and drug screening was also reported for DKC [117].
By using CRISP/Cas9 genome editing system Woo et al.
reported the genetic correction of mutation in DKC1 in
patient specific IPSC as well as introduction of DKC1 mutation
in wild type iPSC. As expected, the corrected DKC1-iPSC
showed high telomerase activity, whereas DKC1 mutant- iPSC
showed lower telomerase activity than wildtype controls.
Interestingly, this study also provided data that supported the
link between DKC1 and Wnt signaling pathway by showing
restoration of telomere length, telomere capping and reduc-
tion of p53BP1 telomere foci upon application of the Wnt
agonist CHIR99021 in DKC-iPSC, indicating that both gene
editing and manipulation of signaling pathway provide poten-
tial avenues for treatment of BMFS.
To date, allogeneic HSC transplantation from HLA-identical
healthy donors remains the only curative therapy for BMFS
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patients. The possibility of performing gene correction
approaches in patients HSCs together with an improved yield of
HSC expansion so that sufficient numbers of cells for autologous
transplantation can be achieved, offers a revolutionary prospect
for the field of BMFS. This will require a reduction in off-target
mutagenesis; however with the pace the field is progressing,
one would hope that this is within our reach very soon.
GENERATION OF IN VITRO CELLULAR MODELS THAT HAVE NOT
BEEN MODELED IN ANIMALS
CAMT-hiPSC
CAMT is characterized by the loss of function or deletion of
the thrombopoietin (TPO) receptor encoded by the MPL
gene, resulting in loss of megakaryocytes (MK) in the bone
marrow, severe thrombocytopenia and development of fatal
BMF later in life. Hirata et al. investigated the mechanisms
involved in the MPL signaling and the development of MK/
Erythrocyte progenitor (MEP) by generating hiPSCs from
CAMT patients carrying MPL mutations [118]. The resultant
CAMT-hiPSCs failed to generate MKs and platelets after hema-
topoietic differentiation, thus recapitulating the typical feature
of human disease: thrombocytopenia. Likewise, CAMT-hiPSCs
displayed impaired colony formation capability especially with
regard to erythrocytes and megakaryocytes, demonstrating a
critical role for MPL signaling in the formation of the common
MEP progenitor which is able to generate both lineages. Ret-
roviral transduction of MPL transgene in CAMT-hiPSCs
restored the differentiation potential of the CAMT to generate
MK, platelets and erythrocytes to similar levels as in control
hiPSCs. Interestingly, excessive expression of MPL transgene
led to a dysregulation of thrombopoiesis and defective mega-
karyopoiesis suggesting that MPL signaling is finely regulated
and levels of expression must fall within a precise expression
window for normal development of thrombopoiesis. These
insights gained through the hiPSC approach are particularly
important for designing curative gene correction strategies
which should aim to restore an appropriate level of MPL
expression.
MDS-hiPSC
MDS is the most common form of primary BMF. The somatic
loss of the long arm of chromosome 7 (del (7q) is one of the
most characteristic chromosomal abnormalities in MDS.
Recently, Kotani et al. derived hiPSCs clones that displayed
normal karyotype as well as clones with del(7q) from MDS
patients [119]. Whereas normal isogenic hiPSCs were able to
generate hematopoietic progenitors, MDS-hiPSCs displayed a
reduced hematopoietic differentiation potential and clono-
genic capacity in all myeloid lineages. Furthermore, MDS-
hiPSCs showed an increase in cell death rate during differenti-
ation. These observations are consistent with the phenotype
observed in primary MDS cells. Interestingly, the authors
observed a spontaneous dosage correction in one of the
clones which acquired a 30 Mb region of a telomeric part of
chromosome 7q (chr7q) and which upon differentiation
showed a fully restored hematopoietic potential to a level
similar to normal hiPSCs. This suggests that the defect respon-
sible for the abnormal hematopoietic phenotype is localized
in this region. Gene expression comparison between del(7q)
MDS clones and chr7q dosage corrected clones allowed the
authors to identify 4 haploinsuficient candidate genes whose
forced expression could partially rescue the hematopoietic
defects in del(7q) MDS iPSC. This study offers an interesting
approach for functional mapping and identification of haplo-
insufficient genes involved in large-scale chromosomal
deletions-associated disorders such as MDS using the hiPSC
technology.
SUMMARY
In the last 20 years, great progress has been achieved in
identifying new genetic causes/susceptibilities of inherited
BMFS, which has resulted in better genotype-phenotype cor-
relations, improved diagnosis and clinical treatments. A large
number of mouse models have been created enabling gener-
ation of insights into disease mechanisms and pathology.
Nevertheless, the inability of gene knock-ins/out to mimic
the precise nature of human mutations and especially hap-
ploinsufficiency together with differences in DNA damage
tolerance, telomere length and short life span have under-
mined their utility in mimicking the full spectrum of BMFS
(Fig. 1). The advent of induced pluripotency enabling genera-
tion of patient specific hematopoietic cells carrying the
genetic change responsible for the disease has revolutionized
the field and has provided a functional platform for uncover-
ing new signaling pathways and small molecules that can be
explored therapeutically. The tremendous advances made in
the genetic engineering field has enabled in situ gene cor-
rections in patients fibroblasts, hiPSC and HSCs opening new
avenues toward generation of autologous cell replacement
therapies for BMFS. Several improvements need to be
achieved toward the generation of long term reconstituting
HSC from hiPSC, efficient ex vivo expansion of HSCs obtained
from adult bone marrow and reducing the off-site targets of
in situ gene editing; nevertheless the fast pace of progress
made in the field of stem cells and genetic engineering
boasts for a bright and promising future for treatment of
BMFS which could have not been anticipated at the begin-
ning of this century!
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